期刊
JOURNAL OF CLINICAL INVESTIGATION
卷 116, 期 12, 页码 3090-3100出版社
AMER SOC CLINICAL INVESTIGATION INC
DOI: 10.1172/JCI30163
关键词
-
资金
- NCRR NIH HHS [M01 RR00040, M01 RR000040] Funding Source: Medline
- NHLBI NIH HHS [R37 HL055323, HL22633, HL62250, R01 HL055323, P01 HL022633, HL55323, HL70128, P01 HL062250, P01 HL059407, P50 HL070128, HL59407] Funding Source: Medline
- NIDDK NIH HHS [DK06990, R01 DK059533, DK59533] Funding Source: Medline
HDL metabolism represents a major target for the development of therapies intended to reduce the risk of atherosclerotic cardiovascular disease. HDL metabolism is complex and involves dissociation of HDL apolipoprotein and HDL cholesterol metabolism. Advances in our under standing of the molecular regulation of HDL metabolism, macrophage cholesterol efflux, and HDL function will lead to a variety of novel therapeutics.
作者
我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。
推荐
暂无数据